Drugs, medicaments and biological substances causing adverse effects in therapeutic use

Y40 Systemic antibiotics adverse effect

• Y40 Systemic antibiotics adverse effect
• Y40.0 Penicillins adverse effect
• Y40.1 Cefalosporins and other b-lactam antibiotics adverse effect
• Y40.2 Chloramphrenicol group adverse effect
• Y40.3 Macrolides adverse effect
• Y40.4 Tetracyclines adverse effect
• Y40.5 Aminoglycosides adverse effect
• Y40.6 Rifamycins adverse effect
• Y40.7 Antifungal antibiotics adverse effect, systemically used
• Y40.8 Other systemic antibiotics adverse effect
• Y40.9 Systemic antibiotic adverse effect, unspecified

Y41 Other systemic anti-infectives and antiparasitics adverse effect

• Y41 Other systemic anti-infectives and antiparasitics adverse effect
• Y41.0 Sulfonamides adverse effect
• Y41.1 Antimycobacterial drugs adverse effect
• Y41.2 Antimalarials and drugs acting on other blood protozoa adverse effect
• Y41.3 Other antiprotozoal drugs adverse effect
• Y41.4 Anthelminthics adverse effect
• Y41.5 Antiviral drugs adverse effect
• Y41.8 Other specified systemic anti-infectives and antiparasitics adverse effect
• Y41.9 Systemic anti-infectiive and antiparasitic adverse effect, unspecified

Y42 Hormones and their synthetic substitutes and antagonists adverse effect, not elsewhere classified

• Y42 Hormones and their synthetic substitutes and antagonists adverse effect, not elsewhere classified
• Y42.0 Glucocorticoids and synthetic analogues adverse effect
• Y42.1 Thyroid hormones and substitutes adverse effect
• Y42.2 Antithyroid drugs adverse effect
• Y42.3 Insulin and oral hypoglycaemic [antidiabetic] drugs adverse effect
• Y42.4 Oral contraceptives adverse effect
• Y42.5 Other estrogens and progestogens adverse effect
• Y42.6 Antigonadotrophins, antiestrogens, antiandrogens adverse effect, not elsewhere classified
• Y42.7 Androgens and anabolic congeners adverse effect
• Y42.8 Other and unspecified hormones and their synthetic substitutes adverse effect
• Y42.9 Other and unspecified hormone antagonists adverse effect

Y43 Primarily systemic agents adverse effect

• Y43 Primarily systemic agents adverse effect
• Y43.0 Antiallergic and antiemetic drugs adverse effect
• Y43.1 Antineoplastic antimetabolites adverse effect
• Y43.2 Antineoplastic natural products adverse effect
• Y43.3 Other antineoplastic drugs adverse effect
• Y43.4 Immunosuppressive agents adverse effect
• Y43.5 Acidifying and alkalizing agents adverse effect
• Y43.6 Enzymes adverse effect, not elsewhere classified
• Y43.8 Other primarily systemic agents adverse effect, not elsewhere classified
• Y43.9 Primarily systemic agent adverse effect, unspecified

Y44 Agent primarily affecting blood constituents adverse effect

• Y44 Agent primarily affecting blood constituents adverse effect
• Y44.0 Iron preparations and other anti-hypochromic-anaemia preparations adverse effect
• Y44.1 Vitamin B12, folic acid and other anti-megaloblastic-anaemia preparations adverse effect
• Y44.2 Anticoagulants adverse effect
• Y44.3 Anticoagulant antagonists, vitamin K and other coagulants adverse effect
• Y44.4 Antithrombotic drugs [platelet-aggregation inhibitors] adverse effect
• Y44.5 Thrombolytic drugs adverse effect
• Y44.6 Natural blood and blood products adverse effect
• Y44.9 Other and unspecified agents affecting blood constituents adverse effect

Y45 Analgesics, antipyretics and anti-inflammatory drugs adverse effect

• Y45 Analgesics, antipyretics and anti-inflammatory drugs adverse effect
• Y45.0 Opioids and related analgesics adverse effect
• Y45.1 Salicylates adverse effect
• Y45.2 Propionic acid derivatives adverse effect
• Y45.3 Other nonsteroidal anti-inflammatory drugs [NSAID] adverse effect
• Y45.4 Antirheumatics adverse effect
• Y45.5 4-Aminophinol derivatives adverse effect
• Y45.8 Other analgesics, antipyretics and anti-inflammatory drugs adverse effect
• Y45.9 Analgesic, antipyretic and anti-inflammatory drug adverse effect, unspecitied

Y46 Antiepileptics and antiparkinsonism drugs adverse effect

• Y46 Antiepileptics and antiparkinsonism drugs adverse effect
• Y46.0 Succinimides adverse effect
• Y46.1 Oxazolidinediones adverse effect
• Y46.2 Hydantoin derivatives adverse effect
• Y46.3 Deoxybarbiturates adverse effect
• Y46.4 Iminostilbenes adverse effect
• Y46.5 Valproic acid adverse effect
• Y46.6 Other and unspecified antiepiltptics adverse effect
• Y46.7 Antiparkinsonism drugs adverse effect
• Y46.8 Antispasticity drugs adverse effect

Y47 Sedatives, hypnotics and antianxiety drugs adverse effect

• Y47 Sedatives, hypnotics and antianxiety drugs adverse effect
• Y47.0 Barbiturates adverse effect, not elsewhere classified
• Y47.1 Benzodiazepines adverse effect
• Y47.2 Cloral derivatives adverse effect
• Y47.3 Paraldehyde adverse effect
• Y47.4 Bromine compounds adverse effect
• Y47.5 Mixed sedatives and hypnotics adverse effect, not elsewhere classified
• Y47.8 Other sedatives, hypnotics and antianxiety drugs adverse effect
• Y47.9 Sedative, hypnotic and antianxiety drug adverse effect, unspecified

Y48 Anaesthetics and therapeutic gases adverse effect

• Y48 Anaesthetics and therapeutic gases adverse effect
• Y48.0 Inhaled anaesthetics adverse effect
• Y48.1 Parenteral anaesthetics adverse effect
• Y48.2 Other and unspecified general anaesthetics adverse effect
• Y48.3 Local anaesthetics adverse effect
• Y48.4 Anaesthetic adverse effect, unspecified
• Y48.5 Therapeutic gases adverse effect

Y49 Psyhotropivc drugs, not elsewhere classified

• Y49 Psyhotropivc drugs, not elsewhere classified
• Y49.0 Tricyclic and tetracyclic antidepressants adverse effect
• Y49.1 Monoamine-oxidase-inhibitor antideprssants adverse effect
• Y49.2 Other and unspecified antidepressants adverse effect
• Y49.3 Phenothiazine antipsychotics and neuroleptics adverse effect
• Y49.4 Butyrophenone and thioxanthene neuroleptics adverse effect
• Y49.5 Other antipsychotics and neuroleptics adverse effect
• Y49.6 Psychodysleptics [hallucinogens] adverse effect
• Y49.7 Psychostimulants with abuse potential adverse effect
• Y49.8 Other psychotropic drugs adverse effect, not elsewhere classified
• Y49.9 Psychotropic drug adverse effect, unspecified

Y50 Central nervous system stimulants adverse effect, not elsewhere classified

• Y50 Central nervous system stimulants adverse effect, not elsewhere classified
• Y50.0 Analeptics adverse effect
• Y50.1 Opioid receptor antagonists adverse effect
• Y50.2 Methylxanthines adverse effect, not eleswhere classified
• Y50.8 Other central nervous system stimulants adverse effect
• Y50.9 Central nervous system stimulant adverse effect, unspecified

Y51 Drugs primarily affecting the autonomic nervous system adverse effect

• Y51 Drugs primarily affecting the autonomic nervous system adverse effect
• Y51.0 Anticholinesterase agents adverse effect
• Y51.1 Other parasympathomimetics [cholinergics] adverse effect
• Y51.2 Ganglionic blocking drugs adverse effect, not elsewhere classified
• Y51.3 Other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics adverse effect, not elsewhere classified
• Y51.4 Predominantly a-adrenoreceptor agonists adverse effect, not elsewhere classified
• Y51.5 Predominantly b-adrenoreceptor agonists adverse effect, not elsewhere classified
• Y51.6 a-Adrenoreceptar antagonists adverse effect, not elsewhere classified
• Y51.7 b-Adrenoreceptor antagonists adverse effect, not elsewhere classified
• Y51.8 Centrally acting and adrenergic-neuron-blocking agents adverse effect, not elsewhere classified
• Y51.9 Other and unspecified drugs primarily affecting the autonomic nervous system adverse effect

Y52 Agents primarily affecting the cardiovascular system adverse effect

• Y52 Agents primarily affecting the cardiovascular system adverse effect
• Y52.0 Cardiac-stimulant glycosides and drugs of similar action adverse effect
• Y52.1 Calcium-channel blockers adverse effect
• Y52.2 Other antidysrhythmic drugs adverse effect, not elsewhere classified
• Y52.3 Coronary vasodilators adverse effect, not elsewhere classified
• Y52.4 Angiotensin-converting-enzyme inhibitors adverse effect
• Y52.5 Other antihypertensive drugs adverse effect, not elsewhere classified
• Y52.6 Antihyperlipidaemic and antierteriosclerotic drugs adverse effect
• Y52.7 Peripheral vasodilators adverse effect
• Y52.8 Antivaricose drugs adverse effect, including sclerosing agents
• Y52.9 Other and unspecified agents primarily affecting the cardiovasular system adverse effect

Y53 Agents primarily affecting the gastrointestinal system adverse effect

• Y53 Agents primarily affecting the gastrointestinal system adverse effect
• Y53.0 Histamine H-receptor antagonists adverse effect
• Y53.1 Other antacids and anti-gastric-secretion drugs adverse effect
• Y53.2 Stimulant laxatives adverse effect
• Y53.3 Saline and osmotic laxatives adverse effect
• Y53.4 Other laxatives adverse effect
• Y53.5 Digestants adverse effect
• Y53.6 Antidiarrhoeal drugs adverse effect
• Y53.7 Emetics adverse effect
• Y53.8 Other agents primarily affecting the gastrointestinal system adverse effect
• Y53.9 Agent primarily affecting the gastrointestinal system adverse effect, unspecified

Y54 Agents primarily affecting water-balance and mineral and uric acid metabolism adverse effect

• Y54 Agents primarily affecting water-balance and mineral and uric acid metabolism adverse effect
• Y54.0 Mineralocorticoids adverse effect
• Y54.1 Mineralocorticoid antagonists [aldosterone antagonists] adverse effect
• Y54.2 Carbonic-anhydrase inhibitors adverse effect
• Y54.3 Binzothiadiazine derivatives adverse effect
• Y54.4 Loop [high-ceiling] diuretics adverse effect
• Y54.5 Other diuretics adverse effect
• Y54.6 Electrolytic, caloric and water-balance agents adverse effect
• Y54.7 Agents affecting calcification adverse effect
• Y54.8 Agents affecting uric acid metabolism adverse effect
• Y54.9 Mineral salts adverse effect, not elsewhere classified

Y55 Agents primarily acying on smooth and skeletal muscles and the respiratory system adverse effect

• Y55 Agents primarily acying on smooth and skeletal muscles and the respiratory system adverse effect
• Y55.0 Oxytocic drugs adverse effect
• Y55.1 Skeletal muscle relaxants [neuromuscular blocking agents] adverse effect
• Y55.2 Other and unspecified agents primarily acting on muscles adverse effect
• Y55.3 Antitussives adverse effect
• Y55.4 Expectorants adverse effect
• Y55.5 Anti-common-cold drugs adverse effect
• Y55.6 Antiasthmatics adverse effect, not elsewhere classified

Y56 Topical agents primarily affecting skin and mucous membrane and ophthalmological otorhinolaryngological and dental drugs adverse effect

• Y56 Topical agents primarily affecting skin and mucous membrane and ophthalmological otorhinolaryngological and dental drugs adverse effect
• Y56.0 Local antifungal, anti-infective and anti-inflammatory drugs adverse effect. not elsewhere classified
• Y56.1 Antipruritics adverse effect
• Y56.2 Local astringents and local detergents adverse effect
• Y56.3 Emollients, demulcents and protectants adverse effect
• Y56.4 Keratolytics, keratoplastics and other hairr treatment drugs and preparations adverse effect
• Y56.5 Ophthalmological drugs and preparations adverse effect
• Y56.6 Otorhinolaryngological drugs and preparations adverse effect
• Y56.7 Dental drugs, topically applied adverse effect
• Y56.8 Other topical agents adverse effect
• Y56.9 Topical agent adverse effect, unspecified

Y57 Other and unspecified drugs and medicaments adverse effect

• Y57 Other and unspecified drugs and medicaments adverse effect
• Y57.0 Appetite depressants [anorectics] adverse effect
• Y57.1 Lipotropic drugs adverse effect
• Y57.2 Antidotes and chelating agents adverse effect, not elsewhere classified
• Y57.3 Alcohol deterrents adverse effect
• Y57.4 Pharmaceutical excipients adverse effect
• Y57.5 X-ray contrast media adverse effect
• Y57.6 Other diagnostic agents adverse effect
• Y57.7 Vitamins adverse effect, not elsewhere classified
• Y57.8 Other drugs and medicaments adverse effect
• Y57.9 Drug or medicament adverse effect, unspecified

Y58 Bacterial vaccines adverse effect

• Y58 Bacterial vaccines adverse effect
• Y58.0 BCG vaccine adverse effect
• Y58.1 Typhoid and paratyphoid vaccine adverse effect
• Y58.2 Cholera vaccine adverse effect
• Y58.3 Plague vaccine adverse effect
• Y58.4 Tetanus vaccine adverse effect
• Y58.5 Diphtheria vaccine adverse effect
• Y58.6 Pertussis vaccine adverse effect, including combinations with a pertussis component
• Y58.8 Mixed bacterial vaccines adverse effect, except combinations with a pertussis component
• Y58.9 Other and unspecified bacterial vaccines adverse effect

Y59 Other and unspecified vaccines and biological substances adverse effect

• Y59 Other and unspecified vaccines and biological substances adverse effect
• Y59.0 Viral vaccines adverse effect
• Y59.1 Rickettsial vaccines adverse effect
• Y59.2 Protozoal vaccines adverse effect
• Y59.3 Immunoglobulin adverse effect
• Y59.8 Other specified vaccines and biological substances adverse effect
• Y59.9 Vaccine or biological substance adverse effect, unspecified